Physician profile
Blake A Booth
NPI 1194915249
$4,002.10
in general payments reported to CMS, 2019-2025
19 companies · $1,295 in 2025
The $1,295 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $870 · 2020: $149 · 2021: $233 · 2022: $290 · 2023: $383 · 2024: $782 · 2025: $1,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,458.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $671.00 | 2019-2025 | Idosetr, Istent Infinite Trabecular Micro-Bypass System Model Is3, Photrexa Cross-Linking Kit |
| Allergan, INC. | $620.73 | 2019-2022 | |
| Alcon Vision LLC | $402.32 | 2019-2025 | Wavelight Refractive Suite, Clareon, Total30 |
| Tarsus Pharmaceuticals, INC. | $336.51 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $256.91 | 2019 | |
| Abbvie INC. | $251.10 | 2022-2025 | Xen Glaucoma Treatment System, Vuity, Lumigan |
| Biotissue Holdings INC. | $236.16 | 2019-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $214.02 | 2019-2024 | Tecnis Iol, Catalys System |
| Harrow Eye, LLC | $179.00 | 2025 | Vevye, Iheezo |
| Dompe US, INC. | $147.46 | 2024-2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $135.79 | 2025 | Acthar |
| Omeros Corporation | $135.43 | 2019 | |
| Rxsight INC | $104.86 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $102.55 | 2019-2025 | Acuvue |
| Sight Sciences, INC. | $58.85 | 2024 | Omni Surgical System |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $51.15 | 2022-2024 | Tyrvaya |
| Ivantis, INC | $46.13 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $34.65 | 2019 | |
| Horizon Therapeutics Plc | $17.48 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Booth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.